Beijing Sun-Novo Pharmaceutical Research Second Quarter 2024 Earnings: EPS: CN¥0.68 (vs CN¥0.62 in 2Q 2023)

Simply Wall St · 09/01 00:12

Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥310.6m (up 36% from 2Q 2023).
  • Net income: CN¥75.8m (up 8.2% from 2Q 2023).
  • Profit margin: 24% (down from 31% in 2Q 2023). The decrease in margin was driven by higher expenses.
  • EPS: CN¥0.68 (up from CN¥0.62 in 2Q 2023).
earnings-and-revenue-growth
SHSE:688621 Earnings and Revenue Growth September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Sun-Novo Pharmaceutical Research Earnings Insights

Looking ahead, revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in China.

Performance of the Chinese Life Sciences industry.

The company's shares are up 8.5% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Beijing Sun-Novo Pharmaceutical Research (of which 1 doesn't sit too well with us!) you should know about.